{"url_path":"/sec/feed/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1326706/0001493152-26-024191-index.html","accession_number":"0001493152-26-024191","cik":"0001326706","ticker":"FEED","issuer_name":"ENvue Medical, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1326706/0001493152-26-024191-index.html","primary_entity_key":"0001326706","primary_entity_name":"ENvue Medical, Inc."},"word_count":41,"has_tables":true,"body_markdown":"**Item\n5. Other Information**\n\n \n\nNone of the Company’s officers or directors adopted, modified or terminated a Rule 10b5-1 trading arrangement\nor a non-Rule 10b5-1 trading arrangement during the Company’s fiscal quarter ended March 31, 2026, as such terms are defined under"}